All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 132 of 206 pages ‹ First < 130 131 132 133 134 > Last ›
HSL1034
Lexchin JR.
Implications of pharmaceutical industry funding on clinical research.
Ann Pharmacother 2005 Jan;39:(1):194-7
http://www.theannals.com/cgi/content/full/39/1/194
HSL1888
Hess R, Chang CC, Conigliaro J, McNeil M.
Understanding physicians' attitudes towards hormone therapy.
Womens Health Issues 2005 Jan-Feb;15:(1):31-8
http://linkinghub.elsevier.com/retrieve/pii/S1049-3867(04)00103-3
HSL2072
Tibdewal S, Gupta M.
Mother's use of medication in their children of preschool age.
Indian J Public Health 2005 Jan-Mar;49:(1):27-9
HSL2111
Meadows AB, Maine LL, Keyes EK, Pearson K, Finstuen K.
Pharmacy executive leadership issues and associated skills, knowledge, and abilities.
J Am Pharm Assoc (Wash DC) 2005 Jan-Feb;45:(1):55-62
HSL4818
Granja M.
[Dangerous liaisons--physicians and pharmaceutical sales representatives].
Acta Med Port 2005 Jan-Feb;18:(1):61-8
http://www.actamedicaportuguesa.com/pdf/2005-18/1/061-068.pdf
HSL4819
Brody H.
The company we keep: why physicians should refuse to see pharmaceutical representatives.
Ann Fam Med 2005 Jan-Feb;3:(1):82-5
http://www.annfammed.org/cgi/content/full/3/1/82
HSL4952
Rataboli PV, Garg A.
Confusing brand names: nightmare of medical profession.
J Postgrad Med 2005 Jan-Mar;51:(1):13-6
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3153&uid=15793332&db=PubMed&url=http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2005;volume=51;issue=1;spage=13;epage=16;aulast=Rataboli
HSL11092
Patten S, Cipriani A, Brambilla , P , Nose , M .
International Dosage Differences in Fluoxetine Clinical Trials
The Canadian Journal of Psychiatry 2005 Jan;50:(1):31-38
HSL15162
Granja M.
LIGAÇÕES PERIGOSAS - Os Médicos e os Delegados de Informação Médica [DANGEROUS LIAISONS – physicians and pharmaceutical sales representatives]
Acta Med Port 2005 Jan-Feb;18:(1):61-68
http://www.actamedicaportuguesa.com/pdf/2005-18/1/061-068.pdf
HSL19782
Pai S
Changing attitudes to drug company sponsorship?
Indian J Med Ethics 2005 Jan;2:(1):
http://www.ijme.in/131le028.html
HSL3601
Chodock R, Yolkut D, Connolly DR.
"Insuring" the continued solvency of pharmaceutical companies in the face of
product liability class actions
Tort Trial Insur Pract Law J 2005 Spr 01;40:(3):997-1017
HSL5141
Lacasse JR.
Consumer advertising of psychiatric medications biases the public against nonpharmacological treatment.
Ethical Hum Psychol Psychiatry 2005 Fal 01;7:(3):175-9
HSL19375
Zipkin DA, Steinman MA
Interactions between pharmaceutical representatives and doctors in training. A thematic review.
J Gen Intern Med 2005;(8):777-86
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1490177/?tool=pubmed
HSL1552
United Kingdom: Companies and organizations in this country ranked by total spending
Lobby Watch - The Center for Public Integrity 2005;
http://www.publicintegrity.org/lobby/profile-pf.aspx?act=countries&year=2003&co=uk
HSL1605
Randall ML, Rosenbaum JR, Rohrbaugh RM, Rosenheck RA.
Attitudes and behaviors of psychiatry residents toward pharmaceutical representatives before and after an educational intervention.
Acad Psychiatry 2005 Spr;29:(1):33-9
http://ap.psychiatryonline.org/cgi/content/abstract/29/1/33
HSL1647
Mohl PC.
Psychiatric training program engagement with the pharmaceutical industry: an educational issue, not strictly an ethical one.
Acad Psychiatry 2005 Sum;29:(2):215-21
http://ap.psychiatryonline.org/cgi/content/full/29/2/215
HSL19043
Schwartz LM, Woloshin S, Welch HG
Can patients interpret health information? An assessment of the medical data interpretation test.
Med Decis Making 2005;25:(3):290-300
http://mdm.sagepub.com/content/25/3/290.long
HSL2331
Muijrers P, Grol R., Sijbrandij J, Janknegt R., Knottnerus J
Differences in prescribing between general practitioners.
Unpublished 2005;
HSL3710
Bezold C, Peck J.
Drug regulation 2056.
Food Drug Law J 2005;60:(2):127-36
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=pubmed
HSL3711
Zelenay JL Jr.
The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
Food Drug Law J 2005;60:(2):261-338
HSL3723
Manchanda P, Honka E.
The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review.
Yale J Health Policy Law Ethics 2005 Sum;5:(2):785-822
http://www.ncbi.nlm.nih.gov/pubmed/16052900
HSL3724
Chin MH.
The patient's role in choice of medications: direct-to-consumer advertising and patient decision aids.
Yale J Health Policy Law Ethics 2005 Sum;5:(2):771-84
HSL3725
Epstein RA.
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Yale J Health Policy Law Ethics 2005 Sum;5:(2):741-70
HSL3726
Eisenberg RS.
The problem of new uses.
Yale J Health Policy Law Ethics 2005 Sum;5:(2):717-39
HSL3747
Benezet JP.
[Pharmaceutical containers and their technological feature at the end of the middle ages].
J Pharm Belg 2005;60:(2):64-75
HSL3754
Elliott C.
Adventure! Comedy! Tragedy! Robots! How bioethicists learned to stop worrying and embrace their inner cyborgs.
J Bioeth Inq 2005;2:(1):18-23
HSL3782
Maynard A.
Quality control in the regulation of pharmaceuticals.
Pharmacoeconomics 2005;23:(5):421-2
HSL3790
Malhi GS, Mitchell PB, Berk M, Goodwin GM.
Mood stabilizers: a labile label.
Acta Psychiatr Scand Suppl 2005;(426):5-6
HSL19042
Woloshin S, Schwartz LM.
Reducing the risk that patients get it wrong.
Gastroenterology 2005;129:(2):748-50
http://www.gastrojournal.org/article/S0016-5085(05)01197-2/abstract
HSL4580
McCann MA.
Dietary supplement labeling: cognitive biases, market manipulation & consumer choice.
Am J Law Med 2005;31:(2-3):215-68
HSL4591
Christenson V.
Drug companies offer major discounts to uninsured.
J Law Med Ethics 2005 Summer;33:(2):399-403
HSL4592
Falit B.
Pharma's commitment to maintaining a clinical trial register: increased transparency or contrived public appeasement?
J Law Med Ethics 2005 Summer;33:(2):391-6
HSL4596
Kahn JP.
Lessons in conflict of interest: the construction of the martyrdom of David Healy and the dilemma of bioethics.
Am J Bioeth 2005 Sum;5:(3):W13
http://taylorandfrancis.metapress.com/(iiz3n4n1mkazbl45vc3o1i45)/app/home/contribution.asp?referrer=parent&backto=issue,31,34;journal,6,24;linkingpublicationresults,1:111605,1
HSL4597
Elliott C.
Lessons in conflict of interest: the construction of the martyrdom of David Healy and the dilemma of bioethics.
Am J Bioeth 2005 Summer;5:(3):
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16006354&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=1526-5161&volume=5&issue=3&spage=W16
HSL4598
Andrews J.
U..S. Military sponsored vaccine trials and la resistance in Nepal.
Am J Bioeth 2005 Summer;5(3):W1-3 2005 Summer;5:(3):W1-3
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16006352&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=1526-5161&volume=5&issue=3&spage=W1
HSL4706
Cain DM, Loewenstein G, Moore DA.
The Dirt on Coming Clean: Perverse Effects of Disclosing Conflicts of Interest
The Journal of Legal Studies 2005;34:1-25
http://www.cbdr.cmu.edu/mpapers/CainLoewensteinMoore2005.pdf
HSL4718
Maurer W.
Creative and innovative statistics in clinical research and development.
Methods Inf Med 2005;44:(4):551-60
HSL4719
Kagan J.
Human morality and temperament.
Nebr Symp Motiv 2005;51:1-32
HSL4727
Arrieta J.
[Off label prescription in nephrology]
Nefrologia 2005;25:(2):103-5
HSL4747
Johnston RE.
Academic science and the business of vaccines.
Arch Virol Suppl 2005;(19):203-6
HSL4748
Halpern GM.
COX-2 inhibitors: a story of greed, deception and death.
Inflammopharmacology 2005;13:(4):419-25
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3152&uid=16354394&db=PubMed&url=http://openurl.ingenta.com/content/nlm?genre=article&issn=0925-4692&volume=13&issue=4&spage=419&aulast=Halpern
HSL4749
Abrahams E, Ginsburg GS, Silver M.
The Personalized Medicine Coalition: goals and strategies.
Am J Pharmacogenomics 2005;5:(6):345-55
HSL4786
Castresana L, Mejia R, Aznar M.
[The attitude of physicians regarding the promotion strategies of the pharmaceutical industry].
Medicina (B Aires) 2005;65:(3):247-51
HSL4797
Chandra A, Miller M.
A closer look at the concept, historical overview, and value of direct-to-consumer advertising of prescription drugs.
Hosp Top 2005 Fall;83:(4):32-6
HSL4828
Stiles GM.
Wyeth responds to criticism.
Md Med 2005 Aut;6:(4):5,
HSL4834
Tomes N.
The great American medicine show revisited
Bull Hist Med. 2005 Winter;79(4):627-63 2005 Wint;79:(4):627-63
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3354&uid=16327082&db=PubMed&url=http://muse.jhu.edu/cgi-bin/resolve_openurl.cgi?issn=0007-5140&volume=79&issue=4&spage=627&aulast=Tomes
HSL4838
Klanica K.
Conflicts of interest in medical research: how much conflict should exceed legal boundaries?
J Biolaw Bus 2005;8:(3):37-45
HSL4847
Polonuer JL.
[Strategies for drug promotion].
Medicina (B Aires) 2005;65:(4):373-6
HSL4857
van Mosseveld C.
Pharmaceutical expenditure compared across countries.
Can J Clin Pharmacol 2005 Fal;12:(3):e269-75
http://www.cjcp.ca/pdf/CJCP_04-048_e269.pdf
HSL4880
Longest BB Jr, Rohrer WM.
Communication between public health agencies and their external stakeholders.
J Health Hum Serv Adm 2005 Fal;28:(2):189-217
HSL4927
Caulfield T.
Commentary: an independent voice?: conflicts of interest and research on ethical, legal and social issues.
Health Law Rev 2005;13:(2-3):114-6
HSL4928
Caulfield T.
Legal and ethical issues associated with patient recruitment in clinical trials: the case of competitive enrolment.
Health Law Rev 2005;13:(2-3):58-61
HSL4929
Lemmens T.
Federal regulation of REB review of clinical trials: a modest but easy step towards an accountable REB review structure in Canada.
Health Law Rev 2005;13:(2-3):39-50
HSL4944
Regnstrom K, Burgess DJ.
Pharmacogenomics and its potential impact on drug and formulation development.
Crit Rev Ther Drug Carrier Syst 2005;22:(5):465-92
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=4847&uid=16313234&db=PubMed&url=http://www.begellhouse.com/journals/3667c4ae6e8fd136,0f80ebac03395679,22c907bb0f290242.html
HSL4988
Mastai R.
[Clinical practice and pharmaceutical industry: an always difficult relationship].
Acta Gastroenterol Latinoam 2005;35:(4):209-10
HSL4992
Lau Y.
Is banning direct to consumer advertising of prescription medicine justified paternalism?
J Bioeth Inq 2005;2:(2):69-74
HSL4993
Jordens C, Anderson L.
Should we be concerned about direct-to-consumer advertising of prescription drugs?
J Bioeth Inq 2005;2:(2):61-2
HSL5098
Fernandez R, Gao C, Genkin W, Ghandi T, Graham R, Hou J, Hsu E, Hwang J.
Changing perspectives on dental advertising.
J Am Coll Dent 2005 Fall;72:(3):24-6
HSL5099
Adamjee A, Alfi D, Agarwal D, Braithwaite Y, Chan J, Chey M, Cho H, Choi C.
What does the fact of advertising convey to patients?
J Am Coll Dent 2005 Fall;72:(3):22-3
HSL5212
Cohen JG.
Recent developments in health law. Merck and the Vioxx decision: playing by the changing rules of the chemical exposure game
J Law Med Ethics 2005 Wint 00;33:(4):866-9
HSL5238
Holbrook A, Grootendorst P, Willison D, Goldsmith C, Sebaldt R, Keshavjee K, Gaebel K.
Can current electronic systems meet drug safety and effectiveness requirements?
AMIA Annu Symp Proc 2005;335-9
HSL5372
Regnier K, Kopelow M, Lane D, Alden E.
Accreditation for learning and change: quality and improvement as the outcome.
J Contin Educ Health Prof 2005 Sum;25:(3):174-82
http://www3.interscience.wiley.com/cgi-bin/abstract/112093715/ABSTRACT?CRETRY=1&SRETRY=0
HSL5421
Jureidini JN, Tonkin A.
Suicide and antidepressants in children (editorial)
Australian Prescriber 2005;28:110-1
http://www.australianprescriber.com/magazine/28/5/110/1/
HSL5439
Campo K, De Staebel O, Gijsbrechts E, van Waterschoot W.
Physicians' decision process for drug prescription and the impact of pharmaceutical marketing mix instruments.
Health Mark Q 2005;22:(4):73-107
HSL5440
Macias W, Stavchansky Lewis L.
How well do direct-to-consumer, DTC, prescription drug web sites meet FDA guidelines and public policy concerns?
Health Mark Q 2005;22:(4):45-71
HSL5441
Parker RS, Pettijohn CE.
Pharmaceutical drug marketing strategies and tactics: a comparative analysis of attitudes held by pharmaceutical representatives and physicians.
Health Mark Q 2005;22:(4):27-43
HSL19040
Woloshin S, Schwartz LM, Welch HG
Patients and medical statistics. Interest, confidence, and ability.
J Gen Intern Med 2005;20:(11):996-1000
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1490265/?tool=pubmed
HSL5579
Mansfield PR, Raven MK, Jureidini JN.
Depressed youth, suicidality and antidepressants
MJA 2005;183:(5):275-276
http://www.mja.com.au/public/issues/183_05_050905/letters_050905_fm-1.html
HSL5740
Curry TJ, Jarosch J, Pacholok , S.
Are Direct to Consumer Advertisements of Prescription Drugs Educational?: Comparing 1992 to 2002.
Journal of Drug Education 2005;35:(3):217-232
HSL5753
Miller D .
Commentary: Psychologically Naive Assumptions about the Perils of Conflicts of Interest
Moore , D A, Cain , Dm , Loewenstein G. Conflicts of interest: Challenges and solutions in business, law, medicine, and public policy. New York, NY: Cambridge University Press 2005
HSL5784
Seamon MJ, Clauson KA.
Ephedra: yesterday, DSHEA, and tomorrow--a ten year perspective on the Dietary Supplement Health and Education Act of 1994.
J Herb Pharmacother 2005;5:(3):67-86
HSL5842
Lambert BL, Lin SJ, Tan H.
Designing safe drug names.
Drug Saf 2005;28:(6):495-512
HSL7411
Gilad J, Moran L, Schlaeffer F, Borer A.
Antibiotic drug advertising in medical journals.
Scand J Infect Dis 2005;37:(11-12):910-2
http://www.ncbi.nlm.nih.gov/pubmed/16308229
HSL8777
Singh AR, Singh SA.
The connection between academia and industry
Mens Sana Monographs 2005;3:(1):5-35
http://www.msmonographs.org/article.asp?issn=0973-1229;year=2005;volume=3;issue=1;spage=5;epage=35;aulast=Singh
HSL8778
Singh AR, Singh SA.
Public welfare agenda or corporate research agenda?
Mens Sana Monographs 2005;3:(1):41-80
http://www.msmonographs.org/article.asp?issn=0973-1229;year=2005;volume=3;issue=1;spage=41;epage=80;aulast=Singh
HSL8824
Kassirer JP.
On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health
New York: Oxford University Press, USA 2005
http://www.oup.com/us/catalog/general/subject/Economics/Health/?view=usa&ci=9780195300048
HSL8825
Abramson J.
Overdosed America: The Broken Promise of American Medicine
New York: Harper Collins 2005
http://www.harpercollins.com/books/9780060568535/Overdosed_America/index.aspx
HSL8826
Moynihan R, Cassels A.
Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients
New York: Nation Books 2005
http://web.archive.org/web/20070416141611/http://www.nationbooks.org/book.mhtml?t=sickness
HSL8994
Moore DA, Cain DM, Loewenstein G, Bazerman MH.
Conflicts of Interest: Challenges and Solutions in Business, Law, Medicine, and Public Policy
New York: Cambridge University Press 2005
http://www.cambridge.org/catalogue/catalogue.asp?isbn=9780511128370&ss=fro
HSL19377
Wells G, Shea B, O'Connell D, Peterson J, Welch V, et al
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis
OHRI 2005
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
HSL9987
Lexchin J.
Intellectual propety rights and the Canadian pharmaceutical marketplace: Where do we go from here?
International Journal of Health Services 2005;35:(2):237 - 256
http://baywood.metapress.com/(iurdbb45zrns2y55w4i3yn45)/app/home/contribution.asp?referrer=parent&backto=issue,2,13;journal,9,146;linkingpublicationresults,1:300313,1
HSL9988
Mintzes B, Lexchin J.
Do higher drug costs lead to better health?
Can J Clin Pharmacol 2005 Win;12:(1):e22-7
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16055941&query_hl=8&itool=pubmed_DocSum
HSL10299
Narhi U, Vanakoski J, Sihvo S.
Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects.
Clin Drug Investig 2005;25:(4):243-8
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17523774
HSL12608
Harp TN, McKenna M, Shute N.
Media, law, and the public's health.
J Law Med Ethics 2005 Win;33:(4):
http://www.ncbi.nlm.nih.gov/pubmed/16689163?dopt=Abstract
HSL13288
Kotabe M, Peloso A, Gregory GD, Noble G, MacArthur W, Neal C, Riege A.
International Marketing: An Asia Pacific Focus
Milton, Qld: John Wiley and Sons Australia, Ltd. 2005
http://web.archive.org/web/20060824005525/http://www.johnwiley.com.au/highered/im/index.htm
HSL16340
Grosjean O
La santé Ã quel prix? Bruxelles: Couleur Livres 2005
http://www.educationsante.be/es/article.php?id=672
HSL16347
Peneff J
La France malade de ses médecins Paris: Les empêcheurs de penser en rond 2005
http://doctorants.mshparisnord.org/actualite/article.php3?id_article=26
HSL16350
Urfalino P
Le grand méchant loup pharmaceutique. Angoisse ou vigilance? Paris: Textuel 2005
http://www.amazon.fr/grand-méchant-loup-pharmaceutique-vigilance/dp/2845971621
HSL17364
Rothman KJ, Greenland S.
Causation and causal inference in epidemiology.
Am J Public Health 2005;95:
http://ajph.aphapublications.org/cgi/content/full/95/S1/S144?view=long&pmid=16030331
HSL19041
Schwartz LM, Woloshin S, Birkmeyer JD
How do elderly patients decide where to go for major surgery? Telephone interview survey.
BMJ 2005 8;20:(11):996-1000
http://www.bmj.com/content/331/7520/821.long
HSL19385
Chintagunta PK, Desiraju R
Strategic Pricing and Detailing Behavior in International Markets
Marketing Science 2005;24:(1):67-80
http://mktsci.journal.informs.org/cgi/content/abstract/24/1/67
HSL20030
Costa C, Papacosta C
Doctors versus Drug Reps: The Corruption of Medical Science
New Doctor 2005;82:24-25
http://search.informit.com.au/documentSummary;dn=927871162682224;res=IELFSC
HSL725
Associated Press.
Eli Lilly Said to Know of Prozac Risks
Associated Press 2004 Dec 31
HSL727
Reuters .
FDA Warns Barr Over Seasonale Commercial
Reuters 2004 Dec 31
HSL5471
Mansfield PR, Jureidini JN, Parry P.
The belief that fluoxetine is effective for depressed children persists but is unjustified
BMJ 2004 Dec 31;330:
http://bmj.bmjjournals.com/cgi/eletters/330/7481/7
HSL718
Meier B .
Medicine's Data Gap: Doctors, Too, Ask: Is This Drug Right?
The New York Times 2004 Dec 30
HSL726
Goldstein , R .
Intimidation, Politics and Drug Industry Cripple U.S. Medicine
Inter Press Service 2004 Dec 30
HSL730
Reuters.
Celebrex Prescriptions Plunge After Risks Identified
The Wall Street Journal 2004 Dec 30
HSL717
The ASSOCIATED.
Family of woman killed by AIDS test drug sues doctors
USA TODAY 2004 Dec 29
HSL777
Maher S.
US drug makers pressure Canberra
The Australian 2004 Dec 29
Page 132 of 206 pages ‹ First < 130 131 132 133 134 > Last ›
